MoonLake Immunotherapeutics ($MLTX) Insider Trading & Smart Money Activity
MoonLake Immunotherapeutics ($MLTX) has 9 insider trades, 2 13F position changes and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 2 insiders sold ($3.12M), net -$3.12M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 2
- Net insider $ (12 mo)
- -$3.12M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 1
MLTX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 2 |
| Q2 2026 | 0 | 5 · $3.12M | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All MLTX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | Leerink Partners | Reiterates to buy | PT $29 | -0.3% | -3.6% | Read | |||||
| Insider | Matthias BodenstedtChief Financial Officer | Sell (Open-market sale) 10b5-1 | 39.12K sh | $862.20K | -10.2% | -14.5% | — | ||||
| Insider | Matthias BodenstedtChief Financial Officer | Sell (Open-market sale) 10b5-1 | 2.79K sh | $54.76K | +4.1% | -0.8% | Read | ||||
| Insider | Ramnik Xavier | Buy (Grant or award) | 22.20K sh | +4.2% | +2.6% | Read | |||||
| Insider | Kristian ReichChief Scientific Officer | Sell (Open-market sale) 10b5-1 | 50K sh | $971.50K | +4.2% | +2.6% | — | ||||
| Insider | Phillips Andrew John | Buy (Grant or award) | 22.20K sh | +4.2% | +2.6% | Read | |||||
| Insider | Catherine Moukheibir | Buy (Grant or award) | 22.20K sh | +4.2% | +2.6% | Read | |||||
| Insider | Spike Loy | Buy (Grant or award) | 22.20K sh | +4.2% | +2.6% | Read | |||||
| Insider | Matthias BodenstedtChief Financial Officer | Sell (Open-market sale) 10b5-1 | 15.08K sh | $296.81K | +4.2% | +2.6% | Read | ||||
| Insider | Kristian ReichChief Scientific Officer | Sell (Open-market sale) 10b5-1 | 50K sh | $935K | +11.8% | +0.2% | Read | ||||
| 13F | Avoro Capital Advisors | Sold out | -2M sh | +3.9% | -4.8% | -6.7% | Read | ||||
| 13F | Avoro Capital Advisors | Sold out | -2M sh | +3.9% | -4.8% | -6.7% | Read |
1W / 1M / 6M = how MLTX moved from the trade or filing date.
Insider trading in MLTX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Matthias Bodenstedt | Chief Financial Officer | 3 | -$1.21M | Jun 22, 2026 | |
| Kristian Reich | Chief Scientific Officer | 2 | -$1.91M | Jun 17, 2026 | |
| Ramnik Xavier | 1 | — | Jun 17, 2026 | ||
| Phillips Andrew John | 1 | — | Jun 17, 2026 | ||
| Catherine Moukheibir | 1 | — | Jun 17, 2026 | ||
| Spike Loy | 1 | — | Jun 17, 2026 |
Institutions moving MLTX (13F)
Analyst ratings on MLTX
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Leerink Partners | Reiterates | buy | $29 | -0.3% | -3.6% | Read |
Frequently asked questions
Are MLTX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 2 insiders made 5 open-market sales worth $3.12M, a net -$3.12M.
What is the latest insider trade in MLTX?
Matthias Bodenstedt, Chief Financial Officer filed a sell (open-market sale) of 39.12K sh worth $862.20K on Jun 22, 2026.
Which institutions changed their MLTX positions?
Recent 13F filers moving the stock include Avoro Capital Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.